Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Related Keywords

Guangzhou ,Guangdong ,China ,Georgia ,United States ,Shanghai ,Hong Kong ,New Jersey ,Atlanta ,Boston ,Massachusetts ,Beijing ,Nanjing ,Jiangsu ,American ,Wei Xu ,Daobin Zhou ,Orelabrutinib Monotherapy ,Prnewswire Innocare Pharma ,Jianyong Li ,Ming Hou ,Waldenstrom Macroglobulinemia ,Chunhua Lu ,American Society Of Hematology ,China National Medical Products Administration ,Drug Administration ,Care Pharma ,American Society ,Annual Meeting ,Professor Daobin Zhou ,Chronic Lymphocytic ,Small Cell Leukemia ,Primary Immune Thrombocytopenia ,Professor Ming Hou ,Refractory Waldenstrom ,Refractory Chronic Lymphocytic ,Small Lymphocytic Lymphoma ,Updated Long Term Results ,Selective Bruton ,Tyrosine Kinase ,Chronic Lymphocytic Leukemia ,Mantle Cell Lymphoma ,Marginal Zone Lymphoma ,Central Nervous System Lymphoma ,Breakthrough Therapy Designation ,Multiple Sclerosis ,Systemic Lupus Erythematosus ,Business ,Health ,Pr Newswire ,Leukemia ,